Search results
Is This Monster Stock on the Verge of a Home Run?
Motley Fool· 2 years agoLate last month, AstraZeneca's (NASDAQ: AZN) rare disease drug called Ultomiris received the green light from the European Commission to treat adult...
Amgen bets on ChemoCentryx's rare disease drug in $3.7 billion deal
Reuters via Yahoo News· 2 years ago(Reuters) -Amgen Inc on Thursday agreed to buy ChemoCentryx Inc for $3.7 billion to gain access to a...
World first as genetically modified pig kidney transplanted into living human
The Telegraph via Yahoo News· 2 months agoThe organ had 69 genetic alterations to make it less porcine and safer for humans - Michelle Rose A...
BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake
Investor's Business Daily· 7 months agoActivist investor Elliott Investment Management has reportedly built a $1 billion stake in BioMarin...
Worried About a Recession? Park Your Money In These 2 High-Yielding Dividend Stocks
Motley Fool· 2 years agoTwo stocks that risk-averse investors should consider today are AstraZeneca (NASDAQ: AZN) and...
Two Dutchess County men accused of insider trading
Poughkeepsie Journal via Yahoo News· 11 months agoTwo Dutchess County men were among four defendants arrested in connection with a federal insider trading case announced this week. Damian Williams, the...
FTSE 100: AstraZeneca ups forecast as COVID treatments boost sales
Yahoo Finance UK· 2 years agoShares in the FTSE 100 drugmaker fell in early trade on Friday in London. Photo: Artur...
AstraZeneca To Acquire Blood-Pressure Drugmaker In $1.8 Billion Deal
Investor's Business Daily· 1 year agoAstraZeneca on Monday said it has agreed to buy CinCor Pharma, maker of clinical-stage blood...
Amgen Aims To Stanch Generic Losses With $3.7 Billion ChemoCentryx Buyout
Investor's Business Daily· 2 years agoAmgen agreed to buy ChemoCentryx for $3.7 billion on Thursday, leading CCXI stock to rocket....
AstraZeneca Makes A Break For A Buy Point On Massive Third-Quarter Growth
Investor's Business Daily· 2 years agoAstraZeneca leaned on cancer and diabetes drugs in the third-quarter, leading to double-digit sales...
